Fig. 3.

Bortezomib sensitises chemotherapy-resistant MPM cells to apoptosis by eliciting an elevated UPR. a, b Immunoblots for apoptotic markers in 2D and 3D cells (MESO-1) after treated with bortezomib (0.1 μM) for indicated time periods. Quantification of the protein level was shown underneath. c, d FACS analysis for apoptotic cell death in 2D and 3D cells (MESO-1) after treated with bortezomib for 48 h. e Antibody-based array assay for apoptosis-related proteins in 2D and 3D cells treated with bortezomib (0.1 μM) or vehicle (DMSO) for 6 h. The relative level (bortezomib vs. vehicle) of proteins that were perturbed by bortezomib is shown to the right. The protein level in vehicle-treated cells was set as 1